

Michael BÃ¶hm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3820666/publications.pdf>

Version: 2024-02-01

436
papers

78,231
citations

1463

107
h-index

517

267
g-index

452
all docs

452
docs citations

452
times ranked

42565
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	2.2	5,681
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
3	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	2.2	5,233
4	2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 2013, 31, 1281-1357.	0.5	4,251
5	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	27.0	4,108
6	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	27.0	2,821
7	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.1	2,307
8	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
9	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet, The, 2010, 376, 875-885.	13.7	2,119
10	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2) Trial. New England Journal of Medicine, 2014, 371, 125-133.	13.7	2,002
11	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Journal of Heart Failure, 2008, 10, 933-989.	7.1	1,893
12	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. New England Journal of Medicine, 2015, 373, 929-938.	27.0	1,827
13	Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal, 2005, 26, 215-225.	2.2	1,392
14	Rosuvastatin in Older Patients with Systolic Heart Failure. New England Journal of Medicine, 2007, 357, 2248-2261.	27.0	1,330
15	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
16	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, The, 2010, 376, 886-894.	13.7	769
17	Update on Myocarditis. Journal of the American College of Cardiology, 2012, 59, 779-792.	2.8	758
18	Cardiovascular Disease in Chronic Kidney Disease. Circulation, 2021, 143, 1157-1172.	1.6	680

#	ARTICLE	IF	CITATIONS
19	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	7.1	630
20	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017, 390, 2160-2170.	13.7	597
21	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018, 391, 2346-2355.	13.7	597
22	Cardiovascular remodelling in coronary artery disease and heart failure. <i>Lancet, The</i> , 2014, 383, 1933-1943.	13.7	589
23	Predictors of Outcome in Patients With Suspected Myocarditis. <i>Circulation</i> , 2008, 118, 639-648.	1.6	576
24	Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. <i>Lancet, The</i> , 2014, 383, 622-629.	13.7	556
25	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
26	Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension. <i>Circulation</i> , 2011, 123, 1940-1946.	1.6	541
27	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , 2018, 391, 2335-2345.	13.7	526
28	Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 59, 901-909.	2.8	466
29	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018, 39, 26-35.	2.2	426
30	Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. <i>Circulation</i> , 2012, 126, 2976-2982.	1.6	420
31	Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2150-2158.	2.8	405
32	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	27.0	381
33	Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy. <i>Circulation</i> , 2010, 122, 900-909.	1.6	377
34	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	1.7	362
35	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq1 1 0.784314 rgBT /Ove 1444-1451.	13.7	351
36	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	7.4	340

#	ARTICLE	IF	CITATIONS
37	Renal Denervation in Moderate to Severe CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1250-1257.	6.1	322
38	Physical Exercise Prevents Cellular Senescence in Circulating Leukocytes and in the Vessel Wall. Circulation, 2009, 120, 2438-2447.	1.6	314
39	Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. Journal of Hypertension, 2009, 27, 1360-1369.	0.5	311
40	Reversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure. Cell Metabolism, 2015, 22, 472-484.	16.2	307
41	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2013, 309, 1125.	7.4	297
42	Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. European Heart Journal, 2011, 32, 2034-2041.	2.2	292
43	Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. Hypertension, 2012, 60, 419-424.	2.7	289
44	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation, 2017, 136, 1374-1383.	1.6	289
45	Elevated Cytosolic Na ⁺ Increases Mitochondrial Formation of Reactive Oxygen Species in Failing Cardiac Myocytes. Circulation, 2010, 121, 1606-1613.	1.6	273
46	Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Research, 2002, 942, 23-30.	2.2	270
47	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal, 2011, 32, 2507-2515.	2.2	264
48	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). European Journal of Heart Failure, 2019, 21, 665-675.	7.1	264
49	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet, The, 2017, 389, 2226-2237.	13.7	263
50	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. European Heart Journal, 2017, 38, 2671-2679.	2.2	243
51	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. Circulation, 2013, 128, 132-140.	1.6	240
52	Heart Rate Reduction by Ivabradine Reduces Oxidative Stress, Improves Endothelial Function, and Prevents Atherosclerosis in Apolipoprotein E-Deficient Mice. Circulation, 2008, 117, 2377-2387.	1.6	234
53	Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?. Journal of the American College of Cardiology, 2012, 59, 1938-1945.	2.8	233
54	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPPLICITY HTN-2 randomized clinical trial. European Heart Journal, 2014, 35, 1752-1759.	2.2	227

#	ARTICLE	IF	CITATIONS
55	Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2683.	7.4	226
56	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. <i>European Heart Journal</i> , 2013, 34, 2149-2157.	2.2	225
57	Evidence for reduction of norepinephrine uptake sites in the failing human heart. <i>Journal of the American College of Cardiology</i> , 1995, 25, 146-153.	2.8	218
58	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217
59	Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. <i>Clinical Research in Cardiology</i> , 2012, 101, 63-67.	3.3	216
60	Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. <i>Heart Rhythm</i> , 2011, 8, 1436-1443.	0.7	214
61	Vascular Pathophysiology in Response to Increased Heart Rate. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1973-1983.	2.8	213
62	Renal Sympathetic Denervation Suppresses Postapneic Blood Pressure Rises and Atrial Fibrillation in a Model for Sleep Apnea. <i>Hypertension</i> , 2012, 60, 172-178.	2.7	213
63	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	7.1	205
64	Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. <i>European Journal of Heart Failure</i> , 2009, 11, 299-303.	7.1	201
65	Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. <i>Clinical Research in Cardiology</i> , 2013, 102, 11-22.	3.3	199
66	Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2885-2896.	2.8	198
67	Changes in Renal Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2481-2493.	2.8	197
68	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50	13.7	197
69	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
70	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. <i>European Heart Journal</i> , 2019, 40, 3474-3482.	2.2	189
71	Fluid status telemedicine alerts for heart failure: a randomized controlled trial. <i>European Heart Journal</i> , 2016, 37, 3154-3163.	2.2	186
72	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. <i>European Heart Journal</i> , 2011, 32, 2395-2404.	2.2	175

#	ARTICLE	IF	CITATIONS
73	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	27.0	174
74	Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both. <i>Circulation</i> , 2010, 121, 1439-1446.	1.6	172
75	First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension. <i>Hypertension</i> , 2015, 65, 766-774.	2.7	172
76	Virus serology in patients with suspected myocarditis: utility or futility?. <i>European Heart Journal</i> , 2011, 32, 897-903.	2.2	170
77	Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. <i>Nature Immunology</i> , 2020, 21, 30-41.	14.5	169
78	Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1766-1775.	2.8	168
79	Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 74-83.	2.8	164
80	Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease. <i>American Journal of Medicine</i> , 2015, 128, 219-228.	1.5	161
81	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , 2017, 38, 1132-1143.	2.2	160
82	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 872-881.	7.1	160
83	Sympatho-renal axis in chronic disease. <i>Clinical Research in Cardiology</i> , 2011, 100, 1049-1057.	3.3	155
84	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
85	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1495-1503.	7.1	154
86	Aldosterone promotes atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2098-2108.	2.2	153
87	Cardiorespiratory Response to Exercise After Renal Sympathetic Denervation in Patients With Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1176-1182.	2.8	142
88	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS Europe Monitoring Study for Heart Failure (MEMS-HF). <i>European Journal of Heart Failure</i> , 2020, 22, 1891-1901.	7.1	142
89	Effects of Renal Sympathetic Denervation on Arterial Stiffness and Central Hemodynamics in Patients With Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1956-1965.	2.8	141
90	Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. <i>European Heart Journal</i> , 2014, 35, 2224-2231.	2.2	140

#	ARTICLE	IF	CITATIONS
91	Device-Based Antihypertensive Therapy. <i>Circulation</i> , 2011, 123, 209-215.	1.6	136
92	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. <i>European Heart Journal</i> , 2016, 37, 2823-2829.	2.2	136
93	Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study. <i>European Heart Journal</i> , 2019, 40, 34-46.	2.2	135
94	Atrial Autonomic Innervation. <i>Journal of the American College of Cardiology</i> , 2014, 63, 215-224.	2.8	133
95	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016, 171, 82-91.	2.7	132
96	Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. <i>Heart Rhythm</i> , 2013, 10, 1525-1530.	0.7	131
97	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
98	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>European Heart Journal</i> , 2012, 33, 2813-2820.	2.2	126
99	Renal denervation: a potential new treatment modality for polycystic ovary syndrome?. <i>Journal of Hypertension</i> , 2011, 29, 991-996.	0.5	124
100	International Expert Consensus Statement. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2031-2045.	2.8	124
101	Effect of Renal Denervation on Neurohumoral Activation Triggering Atrial Fibrillation in Obstructive Sleep Apnea. <i>Hypertension</i> , 2013, 62, 767-774.	2.7	124
102	Heart failure with preserved ejection fraction: uncertainties and dilemmas. <i>European Journal of Heart Failure</i> , 2015, 17, 665-671.	7.1	124
103	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2013, 168, 2214-2220.	1.7	122
104	Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. <i>International Journal of Cardiology</i> , 2013, 167, 2846-2851.	1.7	117
105	Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. <i>Clinical Research in Cardiology</i> , 2014, 103, 149-159.	3.3	117
106	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	7.1	115
107	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL). <i>TJ ETQq1 1 0,784314 rrgBT /Over</i>	13.7	114
108	Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2013, 34, 2839-2849.	2.2	112

#	ARTICLE	IF	CITATIONS
109	Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension. <i>Hypertension</i> , 2015, 65, 193-199.	2.7	109
110	Renal Sympathetic Denervation Provides Ventricular Rate Control But Does Not Prevent Atrial Electrical Remodeling During Atrial Fibrillation. <i>Hypertension</i> , 2013, 61, 225-231.	2.7	108
111	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
112	Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1977-1985.	2.8	104
113	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. <i>European Heart Journal</i> , 2016, 38, ehv325.	2.2	104
114	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1261-1266.	0.5	103
115	Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. <i>European Heart Journal</i> , 2012, 33, 2804-2812.	2.2	102
116	Improvements in Left Ventricular Hypertrophy and Diastolic Function Following Renal Denervation. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1916-1923.	2.8	101
117	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020, 41, 3787-3797.	2.2	101
118	Low-grade albuminuria and cardiovascular risk. <i>Clinical Research in Cardiology</i> , 2007, 96, 247-257.	3.3	99
119	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019, 139, 2542-2553.	1.6	97
120	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 1315-1322.	7.1	96
121	Heart rate reduction in cardiovascular disease and therapy. <i>Clinical Research in Cardiology</i> , 2011, 100, 11-19.	3.3	95
122	Role of autonomic nervous system in atrial fibrillation. <i>International Journal of Cardiology</i> , 2019, 287, 181-188.	1.7	95
123	Renal Denervation in Moderate Treatment-Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1880-1886.	2.8	93
124	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140) mmHg in 10 trials. <i>European Heart Journal</i> , 2018, 39, 3105-3114.	2.2	92
125	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health economic analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 2147-2156.	7.1	91
126	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	2.2	90

#	ARTICLE	IF	CITATIONS
127	Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I _f Inhibitor Ivabradine Trial (SHIFT). <i>European Journal of Heart Failure</i> , 2010, 12, 75-81.	7.1	88
128	The Effects of Direct Thrombin Inhibition with Dabigatran on Plaque Formation and Endothelial Function in Apolipoprotein E-Deficient Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 253-257.	2.5	88
129	European Society of Hypertension position paper on renal denervation 2021. <i>Journal of Hypertension</i> , 2021, 39, 1733-1741.	0.5	88
130	Management of atrial fibrillation in patients with heart failure. <i>European Heart Journal</i> , 2007, 28, 2568-2577.	2.2	87
131	Strategies to improve drug adherence. <i>European Heart Journal</i> , 2011, 32, 264-268.	2.2	87
132	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929.	7.1	86
133	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , 2013, 34, 2263-2270.	2.2	85
134	The Role of Renal Denervation in the Treatment of Heart Failure. <i>Current Cardiology Reports</i> , 2012, 14, 285-292.	2.9	83
135	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I ² Preserve). <i>European Journal of Heart Failure</i> , 2014, 16, 778-787.	7.1	80
136	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015, 36, 434-439.	2.2	80
137	Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk. <i>Hypertension</i> , 2015, 65, 651-661.	2.7	80
138	Renal Denervation in High-Risk Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2879-2888.	2.8	80
139	Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. <i>Journal of Hypertension</i> , 2007, 25, 2317-2324.	0.5	77
140	Device-based therapies for arterial hypertension. <i>Nature Reviews Cardiology</i> , 2020, 17, 614-628.	13.7	77
141	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. <i>Clinical Research in Cardiology</i> , 2015, 104, 1097-1105.	3.3	76
142	Heart Rate Contributes to the Vascular Effects of Chronic Mental Stress. <i>Stroke</i> , 2011, 42, 1742-1749.	2.0	75
143	Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?. <i>Circulation Research</i> , 2014, 115, 400-409.	4.5	75
144	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	4.1	75

#	ARTICLE	IF	CITATIONS
145	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. <i>Clinical Research in Cardiology</i> , 2020, 109, 1079-1098.	3.3	74
146	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 471-484.	2.9	73
147	Renal sympathetic denervation: applications in hypertension and beyond. <i>Nature Reviews Cardiology</i> , 2013, 10, 465-476.	13.7	71
148	Incidence and prevalence of pregnancy-related heart disease. <i>Cardiovascular Research</i> , 2014, 101, 554-560.	3.8	71
149	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019, 40, 743-751.	2.2	70
150	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1017-1028.	2.8	70
151	Catheter-Based Renal Denervation Is No Simple Matter. <i>Journal of the American College of Cardiology</i> , 2014, 64, 644-646.	2.8	68
152	Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. <i>Clinical Research in Cardiology</i> , 2016, 105, 873-879.	3.3	67
153	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2020, 22, 126-135.	7.1	67
154	Renal nerve ablation reduces augmentation index in patients with resistant hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1893-1900.	0.5	66
155	Fluid status monitoring with a wireless network to reduce cardiovascular-related hospitalizations		

#	ARTICLE	IF	CITATIONS
163	Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. <i>European Heart Journal</i> , 2012, 33, 1223-1231.	2.2	59
164	Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. <i>EuroIntervention</i> , 2020, 16, 89-96.	3.2	59
165	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in <scp>SHIFT</scp>. <i>European Journal of Heart Failure</i> , 2014, 16, 810-816.	7.1	58
166	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the <scp>SHIFT</scp> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1294-1301.	7.1	58
167	Circulating microparticles as indicators of peripartum cardiomyopathy. <i>European Heart Journal</i> , 2012, 33, 1469-1479.	2.2	56
168	Heart rate: A global target for cardiovascular disease and therapy along the cardiovascular disease continuum. <i>Journal of Cardiology</i> , 2013, 62, 183-187.	1.9	56
169	Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	56
170	Rationale and design of a large registry on renal denervation: the Global SYMPPLICITY registry. <i>EuroIntervention</i> , 2013, 9, 484-492.	3.2	56
171	Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2015, 104, 911-917.	3.3	55
172	True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. <i>American Heart Journal</i> , 2017, 188, 99-108.	2.7	55
173	Progression of Kidney Injury and Cardiac Remodeling in Obese Spontaneously Hypertensive Rats: The Role of Renal Sympathetic Innervation. <i>American Journal of Hypertension</i> , 2015, 28, 256-265.	2.0	54
174	Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the <scp>SHIFT</scp> Holter substudy. <i>European Journal of Heart Failure</i> , 2015, 17, 518-526.	7.1	54
175	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1890-1897.	1.6	54
176	Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2016, 105, 364-371.	3.3	54
177	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.	2.8	52
178	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	3.9	51
179	Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. <i>American Heart Journal</i> , 2013, 166, 306-314.e7.	2.7	51
180	Renal denervation and heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 608-613.	7.1	51

#	ARTICLE	IF	CITATIONS
181	Rationale and design of the DIGITâ€CHF trial (DIGitoxin to Improve ouTcomes in patients with advanced) Tj ETQq1 1 0.784314 rgBT /Overl Heart Failure, 2019, 21, 676-684.	7.1	51
182	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	1.6	51
183	Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. Clinical Research in Cardiology, 2020, 109, 1446-1459.	3.3	51
184	Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. Clinical Research in Cardiology, 2020, 109, 1500-1506.	3.3	50
185	Beneficial association of Î²-blocker therapy on recovery from severe acute heart failure treatment: Data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial*. Critical Care Medicine, 2011, 39, 940-944.	0.9	49
186	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. European Heart Journal, 2019, 40, 2032-2043.	2.2	47
187	Interstitial remodeling in Î²1-adrenergic receptor transgenic mice. Basic Research in Cardiology, 2007, 102, 183-193.	5.9	46
188	Systolic Blood Pressure in HeartÂFailure With Preserved Ejection Fraction TreatedÂWith Sacubitril/Valsartan. Journal of the American College of Cardiology, 2020, 75, 1644-1656.	2.8	46
189	Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the) Tj ETQq1 1 0.784314 rgBT /Overl Overload, 2019, 21, 145-154.	1.6	45
190	Effects of Electrical Stimulation of Carotid Baroreflex and Renal Denervation on Atrial Electrophysiology. Journal of Cardiovascular Electrophysiology, 2013, 24, 1028-1033.	1.7	44
191	Risk following hospitalization in stable chronic systolic heart failure. European Journal of Heart Failure, 2013, 15, 885-891.	7.1	42
192	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from <scp>SHIFT</scp>. European Journal of Heart Failure, 2014, 16, 426-434.	7.1	42
193	Drug adherence in patients taking oral anticoagulation therapy. Clinical Research in Cardiology, 2014, 103, 173-182.	3.3	42
194	Arterial hypertension â€ Clinical trials update 2021. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 21-31.	2.6	42
195	Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovascular Diabetology, 2021, 20, 6.	6.8	42
196	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure, 2018, 20, 373-381.	7.1	41
197	Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. Journal of Hypertension, 2015, 33, 2519-2525.	0.5	40
198	GuÃa ESC 2021 sobre el diagnÃstico y tratamiento de la insuficiencia cardiaca aguda y crÃnica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	1.2	40

#	ARTICLE	IF	CITATIONS
199	Angiotensin Receptor Blockers versus Angiotensin-Converting Enzyme Inhibitors: Where Do We Stand Now?. <i>American Journal of Cardiology</i> , 2007, 100, S38-S44.	1.6	39
200	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a postâ€œhoc analysis of <sc>SHIFT</sc>. <i>European Journal of Heart Failure</i> , 2016, 18, 1182-1189.	7.1	39
201	Impact of Renal Impairment on Beta-Blocker Efficacy in Patientsâ€œWithâ€œHeartâ€œFailure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2893-2904.	2.8	39
202	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHEMUS trial. <i>European Heart Journal</i> , 2020, 41, 1673-1683.	2.2	39
203	Renal Sympathetic Denervation in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e007421.	3.9	39
204	Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. <i>European Heart Journal</i> , 2009, 30, 1364-1371.	2.2	38
205	Atrial Remodeling Following Catheter-Based Renal Denervation Occurs in a Blood Pressureâ€œ and Heart Rateâ€œIndependent Manner. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 972-980.	2.9	38
206	Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placeboâ€œcontrolled study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2814-2818.	4.4	38
207	Optimal Antagonism of the Renin-Angiotensin-Aldosterone System. <i>Drugs</i> , 2010, 70, 1215-1230.	10.9	37
208	Physician attitudes to blood pressure control. <i>Journal of Hypertension</i> , 2011, 29, 1633-1640.	0.5	37
209	Heart rate and its reduction in chronic heart failure and beyond. <i>European Journal of Heart Failure</i> , 2017, 19, 1230-1241.	7.1	37
210	Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). <i>Clinical Research in Cardiology</i> , 2018, 107, 991-1002.	3.3	37
211	â€œTime is prognosisâ€œ™ in heart failure: timeâ€œtoâ€œtreatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , 2021, 8, 4444-4453.	3.1	37
212	Twenty-Fourâ€œHour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Circulation</i> , 2018, 138, 1602-1604.	1.6	36
213	Myopathic Cardiac Genotypes Increase Risk for Myocarditis. <i>JACC Basic To Translational Science</i> , 2021, 6, 584-592.	4.1	36
214	Interleukin-1Î± Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. <i>Circulation</i> , 2021, 144, 893-908.	1.6	36
215	Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. <i>Atherosclerosis</i> , 2010, 212, 55-62.	0.8	35
216	Renal denervation: effects on atrial electrophysiology and arrhythmias. <i>Clinical Research in Cardiology</i> , 2014, 103, 765-774.	3.3	35

#	ARTICLE	IF	CITATIONS
217	Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. <i>International Journal of Cardiology</i> , 2015, 190, 376-382.	1.7	35
218	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020, 41, 231-238.	2.2	35
219	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	1.6	35
220	Response and non-response to renal denervation: who is the ideal candidate?. <i>EuroIntervention</i> , 2013, 9, R54-R57.	3.2	35
221	Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. <i>International Journal of Cardiology</i> , 2016, 216, 165-167.	1.7	34
222	Confounding Factors in Renal Denervation Trials. <i>Hypertension</i> , 2020, 76, 1410-1417.	2.7	33
223	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 513-525.	7.1	33
224	Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e329-e337.	3.9	33
225	BEAUTIFUL resultsâ€”the slower, the better?. <i>Lancet</i> , The, 2008, 372, 779-780.	13.7	32
226	Exercise Promotes Collateral Artery Growth Mediated by Monocytic Nitric Oxide. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1862-1871.	2.4	32
227	Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles. <i>PLoS ONE</i> , 2017, 12, e0176311.	2.5	32
228	Drug Layering in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 775-783.	4.1	32
229	Orthostatic function after renal sympathetic denervation in patients with resistant hypertension. <i>International Journal of Cardiology</i> , 2013, 169, 418-424.	1.7	31
230	Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. <i>Clinical Research in Cardiology</i> , 2014, 103, 665-673.	3.3	31
231	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. <i>Hypertension</i> , 2017, 70, 938-948.	2.7	31
232	Interaction of systolic blood pressure and resting heart rate with clinical outcomes in takotsubo syndrome: insights from the International Takotsubo Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1021-1030.	7.1	31
233	Heart Rate Reduction by If-Channel Inhibition and its Potential Role in Heart Failure with Reduced and Preserved Ejection Fraction. <i>Trends in Cardiovascular Medicine</i> , 2009, 19, 152-157.	4.9	30
234	Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. <i>Clinical Research in Cardiology</i> , 2009, 98, 513-515.	3.3	30

#	ARTICLE	IF	CITATIONS
235	Loss of Mitochondrial Ca ²⁺ Uniporter Limits Inotropic Reserve and Provides Trigger and Substrate for Arrhythmias in Barth Syndrome Cardiomyopathy. <i>Circulation</i> , 2021, 144, 1694-1713.	1.6	30
236	Cathepsin A mediates susceptibility to atrial tachyarrhythmia and impairment of atrial emptying function in Zucker diabetic fatty rats. <i>Cardiovascular Research</i> , 2016, 110, 371-380.	3.8	29
237	Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. <i>Clinical Research in Cardiology</i> , 2019, 108, 290-297.	3.3	29
238	Marathon running increases circulating endothelial- and thrombocyte-derived microparticles. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 317-324.	1.8	28
239	Effects of Arteriovenous Fistula on Blood Pressure in Patients With End-Stage Renal Disease: A Systematic Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e011183.	3.7	28
240	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 528-538.	7.1	28
241	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020, 109, 289-302.	3.3	28
242	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
243	Effects of face masks on performance and cardiorespiratory response in well-trained athletes. <i>Clinical Research in Cardiology</i> , 2022, 111, 264-271.	3.3	27
244	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1028-1038.	2.8	27
245	Anxiety, depression, quality of life and stress in patients with resistant hypertension before and after catheter-based renal sympathetic denervation. <i>EuroIntervention</i> , 2013, 9, 700-708.	3.2	27
246	Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. <i>Clinical Research in Cardiology</i> , 2016, 105, 601-612.	3.3	26
247	Repeated exposure to transient obstructive sleep apnea-related conditions causes an atrial fibrillation substrate in a chronic rat model. <i>Heart Rhythm</i> , 2021, 18, 455-464.	0.7	26
248	Effect of Combining Ivabradine and Î²-Blockers: Focus on the Use of Carvedilol in the SHIFT Population. <i>Cardiology</i> , 2015, 131, 218-224.	1.4	25
249	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020, 41, 2848-2859.	2.2	25
250	Heart Rate Reduction by Ivabradine Improves Aortic Compliance in Apolipoprotein E-Deficient Mice. <i>Journal of Vascular Research</i> , 2012, 49, 432-440.	1.4	24
251	Effects of Renal Sympathetic Denervation on Exercise Blood Pressure, Heart Rate, and Capacity in Patients With Resistant Hypertension. <i>Hypertension</i> , 2014, 63, 839-845.	2.7	24
252	One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. <i>Clinical Research in Cardiology</i> , 2020, 109, 845-856.	3.3	24

#	ARTICLE	IF	CITATIONS
253	The significance of left ventricular ejection time in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 541-551.	7.1	24
254	Heart rate differentiates urgency and emergency in hypertensive crisis. <i>Clinical Research in Cardiology</i> , 2013, 102, 593-598.	3.3	23
255	Analyses of drugs stored at home by elderly patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2015, 104, 320-327.	3.3	23
256	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. <i>International Journal of Cardiology</i> , 2017, 241, 373-378.	1.7	23
257	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <sc>ASTRONAUT</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 552-562.	7.1	23
258	Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension. <i>Journal of Hypertension</i> , 2017, 35, 148-153.	0.5	23
259	Catheter-based renal denervation as adjunct to pulmonary vein isolation for treatment of atrial fibrillation: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2020, 38, 783-790.	0.5	23
260	Determinants of HIV-1 Late Presentation in Patients Followed in Europe. <i>Pathogens</i> , 2021, 10, 835.	2.8	23
261	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 1044-1052.	7.1	22
262	Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPPLICITY Registry with follow-up data of 3 years. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 304-310.	0.7	22
263	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. <i>Clinical Research in Cardiology</i> , 2015, 104, 1064-1071.	3.3	21
264	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	7.1	21
265	Renal denervation in hypertensive patients not on blood pressure lowering drugs. <i>Clinical Research in Cardiology</i> , 2016, 105, 755-762.	3.3	21
266	PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARMaCHF): rationale and design of a randomized controlled trial, and results of the pilot study. <i>European Journal of Heart Failure</i> , 2018, 20, 1350-1359.	7.1	21
267	MicroRNA-mediated vascular intercellular communication is altered in chronic kidney disease. <i>Cardiovascular Research</i> , 2022, 118, 316-333.	3.8	21
268	Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1-18.	2.8	21
269	Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the <i>I</i> Inhibitor Ivabradine Trial (SHIFT) Trial. <i>Journal of the American Heart Association</i> , 2016, 5, e007881.	3.7	20
270	Modulation of renal sympathetic innervation: recent insights beyond blood pressure control. <i>Clinical Autonomic Research</i> , 2018, 28, 375-384.	2.5	20

#	ARTICLE	IF	CITATIONS
271	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. <i>European Journal of Heart Failure</i> , 2019, 21, 1469-1472.	7.1	20
272	Ejection fraction in heart failure revisited-Where does the evidence start?. <i>European Heart Journal</i> , 2020, 41, 2363-2365.	2.2	20
273	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , 2021, 8, 861-871.	3.1	20
274	The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 3566-3576.	3.1	20
275	Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Stented Renal Arteries. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 813-820.	3.9	19
276	Association of vitamin D status and blood pressure response after renal denervation. <i>Clinical Research in Cardiology</i> , 2014, 103, 41-47.	3.3	19
277	Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 325-333.	7.1	19
278	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension. <i>Journal of Hypertension</i> , 2016, 34, 2480-2486.	0.5	19
279	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. <i>Journal of Hypertension</i> , 2016, 34, 1854-1862.	0.5	19
280	Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension. <i>EuroIntervention</i> , 2018, 14, 121-128.	3.2	19
281	A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2022, 24, 1719-1736.	7.1	19
282	Procollagen propeptides: serum markers for atrial fibrosis?. <i>Clinical Research in Cardiology</i> , 2012, 101, 655-661.	3.3	18
283	Blood pressure variability after catheter-based renal sympathetic denervation in patients with resistant hypertension. <i>Journal of Hypertension</i> , 2015, 33, 2512-2518.	0.5	18
284	The association between different features of sleep-disordered breathing and blood pressure: A cross-sectional study. <i>Journal of Clinical Hypertension</i> , 2018, 20, 575-581.	2.0	18
285	Hypertension: history and development of established and novel treatments. <i>Clinical Research in Cardiology</i> , 2018, 107, 16-29.	3.3	18
286	Timely and individualized heart failure management: need for implementation into the new guidelines. <i>Clinical Research in Cardiology</i> , 2021, 110, 1150-1158.	3.3	18
287	Heart rate: surrogate or target in the management of heart failure?. <i>Heart</i> , 2013, 99, 72-75.	2.9	17
288	Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2016, 118, 1948-1953.	1.6	17

#	ARTICLE	IF	CITATIONS
289	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. <i>Clinical Research in Cardiology</i> , 2018, 107, 642-652.	3.3	17
290	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , 2019, 74, 244-249.	2.7	17
291	Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor. <i>European Journal of Heart Failure</i> , 2019, 21, 482-491.	7.1	17
292	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 725-731.	3.3	17
293	Remote Monitoring With Appropriate Reaction to Alerts Was Associated With Improved Outcomes in Chronic Heart Failure. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008693.	4.8	17
294	Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1493-1503.	1.9	17
295	Treatment of Heart Failure in Real-World Clinical Practice: Findings From the REFLECT-HF Registry in Patients With NYHA Class II Symptoms and a Reduced Ejection Fraction. <i>Clinical Cardiology</i> , 2015, 38, 200-207.	1.8	16
296	Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease. <i>Journal of Hypertension</i> , 2019, 37, 1023-1031.	0.5	16
297	Contemporary scientometric analyses using a novel web application: the science performance evaluation (SciPE) approach. <i>Clinical Research in Cardiology</i> , 2020, 109, 810-818.	3.3	16
298	Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2020, 41, 2556-2569.	2.2	16
299	The current status of renal denervation for the treatment of arterial hypertension. <i>Progress in Cardiovascular Diseases</i> , 2021, 65, 76-83.	3.1	16
300	Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. <i>Cardiology</i> , 2017, 136, 138-144.	1.4	15
301	Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 9-19.	1.8	15
302	Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension. <i>Journal of Hypertension</i> , 2019, 37, 1906-1912.	0.5	15
303	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , 2020, 38, 1829-1840.	0.5	15
304	Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. <i>Journal of Human Hypertension</i> , 2021, 35, 903-911.	2.2	15
305	Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2233-2238.	3.1	15
306	Recent advances in the treatment of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 729-744.	1.5	14

#	ARTICLE	IF	CITATIONS
307	Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 272-280.	1.8	14
308	Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk. <i>Journal of Hypertension</i> , 2014, 32, 1334-1341.	0.5	14
309	Blood Pressure Risk Associations in Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 820-822.	4.1	14
310	Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1960-1970.	7.1	14
311	Pulmonary artery sensor system pressure monitoring to improve heart failure outcomes (PASSPORT-HF): rationale and design of the PASSPORT-HF multicenter randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 1245-1255.	3.3	14
312	Thrombus aspiration in non-ST-elevation myocardial infarction – 12-month clinical outcome of the randomised TATORT-NSTEMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 10-17.	1.0	13
313	Development, establishment and validation of in vitro and ex vivo assays of vascular calcification. <i>Biochemical and Biophysical Research Communications</i> , 2020, 530, 462-470.	2.1	13
314	Device-related risk of atrial fibrillation after closure of patent foramen ovale: a systematic review and meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 583-587.	3.3	13
315	Modulation of the sympathetic nervous system by renal denervation prevents reduction of aortic distensibility in atherosclerosis prone ApoE-deficient rats. <i>Journal of Translational Medicine</i> , 2016, 14, 167.	4.4	12
316	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , 2020, 38, 420-425.	0.5	12
317	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , 2021, 16, e1496-e1502.	3.2	12
318	Expert opinion paper on cardiac imaging after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2021, 110, 938-958.	3.3	12
319	Research Output and International Cooperation Among Countries During the COVID-19 Pandemic: Scientometric Analysis. <i>Journal of Medical Internet Research</i> , 2020, 22, e24514.	4.3	12
320	Comparison of Long-Term Outcomes for Responders Versus Non-Responders Following Renal Denervation in Resistant Hypertension. <i>Journal of the American Heart Association</i> , 2021, 10, e022429.	3.7	12
321	From Evidence to Rationale: Cardiovascular Protection by Angiotensin II Receptor Blockers Compared with Angiotensin-Converting Enzyme Inhibitors. <i>Cardiology</i> , 2010, 117, 163-173.	1.4	11
322	Treating resistant hypertension: role of renal denervation. <i>Integrated Blood Pressure Control</i> , 2013, 6, 119.	1.2	11
323	Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPPLICITY Registry. <i>Journal of Clinical Hypertension</i> , 2017, 19, 833-839.	2.0	11
324	Heart rate: from heart failure to chronic diseases and cancer. Is there a role for supportive care by heart rate reduction?. <i>European Journal of Heart Failure</i> , 2017, 19, 250-252.	7.1	11

#	ARTICLE	IF	CITATIONS
325	Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale. Korean Circulation Journal, 2017, 47, 9.	1.9	11
326	Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency. Cardiovascular Revascularization Medicine, 2018, 19, 845-851.	0.8	11
327	The new SFB/TRR219 Research Centre. European Heart Journal, 2018, 39, 975-977.	2.2	11
328	Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model. Journal of Hypertension, 2018, 36, 2453-2459.	0.5	11
329	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.. ESC Heart Failure, 2019, 6, 1199-1207.	3.1	11
330	Blood pressure targets in the elderly: many guidelines, much confusion. European Heart Journal, 2019, 40, 2029-2031.	2.2	11
331	Time-updated resting heart rate predicts mortality in patients with COPD. Clinical Research in Cardiology, 2020, 109, 776-786.	3.3	11
332	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). American Journal of Cardiology, 2021, 149, 27-35.	1.6	11
333	Hypertension trials update. Journal of Human Hypertension, 2021, 35, 398-409.	2.2	11
334	Therapeutic potential of renal sympathetic denervation in patients with chronic heart failure. EuroIntervention, 2013, 9, R122-R126.	3.2	11
335	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovascular Diabetology, 2022, 21, 12.	6.8	11
336	Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. Clinical Research in Cardiology, 2023, 112, 197-202.	3.3	11
337	A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms. Heart Failure Reviews, 2015, 20, 545-552.	3.9	10
338	Cathepsin A Mediates Ventricular Remote Remodeling and Atrial Cardiomyopathy in Rats With Ventricular Ischemia/Reperfusion. JACC Basic To Translational Science, 2019, 4, 332-344.	4.1	10
339	Renal Denervation: Is It Ready for Prime Time?. Current Cardiology Reports, 2019, 21, 80.	2.9	10
340	Effects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertension. Clinical Research in Cardiology, 2020, 109, 581-588.	3.3	10
341	Cathepsin A contributes to left ventricular remodeling by degrading extracellular superoxide dismutase in mice. Journal of Biological Chemistry, 2020, 295, 12605-12617.	3.4	10
342	The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARMACHF randomized controlled trial. ESC Heart Failure, 2020, 7, 3310-3319.	3.1	10

#	ARTICLE	IF	CITATIONS
343	Research in Atrial Fibrillation. JACC: Clinical Electrophysiology, 2020, 6, 1008-1018.	3.2	10
344	Valvular heart disease in patients with chronic kidney disease. Herz, 2021, 46, 228-233.	1.1	10
345	Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Atherosclerosis, 2021, 330, 8-13.	0.8	10
346	Association of clinic and ambulatory heart rate parameters with mortality in hypertension. Journal of Hypertension, 2020, 38, 2416-2426.	0.5	10
347	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. Hypertension, 2022, 79, 1506-1514.	2.7	10
348	Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. European Journal of Heart Failure, 2022, 24, 1625-1632.	7.1	10
349	Aldosterone Antagonists and Renal Denervation. Hypertension, 2015, 65, 280-282.	2.7	9
350	Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome. Journal of Molecular and Cellular Cardiology, 2018, 122, 34-46.	1.9	9
351	The Current Status of Devices for the Treatment of Resistant Hypertension. American Journal of Hypertension, 2020, 33, 10-18.	2.0	9
352	Adherence to Antihypertensive Drugs Assessed by Hyphenated High-Resolution Mass Spectrometry Analysis of Oral Fluids. Journal of the American Heart Association, 2020, 9, e014180.	3.7	9
353	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. Journal of Hypertension, 2021, 39, 766-774.	0.5	9
354	Changes in quality of life, depression, general anxiety, and heart-focused anxiety after defibrillator implantation. ESC Heart Failure, 2021, 8, 2502-2512.	3.1	9
355	Heart rate and heart failure. Current Opinion in Cardiology, 2013, 28, 326-331.	1.8	8
356	Publication performance of women compared to men in German cardiology. International Journal of Cardiology, 2015, 181, 267-269.	1.7	8
357	Witnessed drug intake before planned denervation—Always harmless?. International Journal of Cardiology, 2015, 179, 125-126.	1.7	8
358	The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes. Medicine (United States), 2016, 95, e3122.	1.0	8
359	Real-time left ventricular pressure-volume loops during percutaneous central arteriovenous anastomosis. European Heart Journal, 2018, 39, 2330-2331.	2.2	8
360	Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study. Integrated Blood Pressure Control, 2022, Volume 15, 11-21.	1.2	8

#	ARTICLE	IF	CITATIONS
361	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
362	Renal Denervation Prevents Atrial Arrhythmogenic Substrate Development in CKD. <i>Circulation Research</i> , 2022, 130, 814-828.	4.5	7
363	Renal Denervation: A Novel Non-pharmacological Approach in Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 330-337.	2.4	6
364	Novel and Nonpharmacologic Approaches to Cardio-Protection in Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 430.	3.5	6
365	Renal Denervation Halts Left Ventricular Remodeling and Dysfunction in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2622-2624.	2.8	6
366	A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model. <i>Clinical Research in Cardiology</i> , 2022, 111, 595-603.	3.3	6
367	Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	6
368	Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTITUDE, FAME II and more. <i>Clinical Research in Cardiology</i> , 2012, 101, 861-874.	3.3	5
369	Effects of renal denervation on atrial arrhythmogenesis. <i>Future Cardiology</i> , 2014, 10, 813-822.	1.2	5
370	Accuracy of pulse rate derived from 24-h ambulatory blood pressure monitoring compared with heart rate from 24-h Holter-ECG. <i>Journal of Hypertension</i> , 2020, 38, 2387-2392.	0.5	5
371	Long-term outcome after thrombus aspiration in non-ST-elevation myocardial infarction: results from the TATORT-NSTEMI trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1223-1231.	3.3	5
372	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021, 39, 1602-1610.	0.5	5
373	Drug adherence and psychosocial characteristics of patients presenting with hypertensive urgency at the emergency department. <i>Journal of Hypertension</i> , 2021, 39, 1697-1704.	0.5	5
374	Optimization of Heart Failure Treatment by Heart Rate Reduction. <i>International Journal of Heart Failure</i> , 2020, 2, 1.	2.7	5
375	Photoinduced skin reactions of cardiovascular drugs—a systematic review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 420-430.	3.0	5
376	Overview of the i-SEARCH Global Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 217-224.	2.2	4
377	Arteriovenous anastomosis—next panacea for hypertension?. <i>Nature Reviews Cardiology</i> , 2015, 12, 197-198.	13.7	4
378	Renal nerve ablation. <i>Heart</i> , 2015, 101, 320-328.	2.9	4

#	ARTICLE	IF	CITATIONS
379	Catheter-based renal denervation in hypertension. <i>Journal of Hypertension</i> , 2018, 36, 41-42.	0.5	4
380	Secondary rise in blood pressure and leg swelling after central arteriovenous anastomosis. <i>Clinical Research in Cardiology</i> , 2019, 108, 574-576.	3.3	4
381	Development and implementation of blood pressure screening and referral guidelines for German community pharmacists. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1807-1816.	2.0	4
382	Blood pressure and renal denervation with ultrasound: another step forward. <i>Lancet</i> , The, 2021, 397, 2441-2443.	13.7	4
383	Sex Differences in Cardiovascular Research: A Scientometric Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e021522.	3.7	4
384	Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. <i>ESC Heart Failure</i> , 2021, , .	3.1	4
385	Chemokine CCL9 Is Upregulated Early in Chronic Kidney Disease and Counteracts Kidney Inflammation and Fibrosis. <i>Biomedicines</i> , 2022, 10, 420.	3.2	4
386	CardioPulse. Catheter-based renal denervation for hypertension treatment: update 2015. <i>European Heart Journal</i> , 2016, 37, 930-3.	2.2	4
387	Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study: reply. <i>European Journal of Heart Failure</i> , 2009, 11, 631-632.	7.1	3
388	Long-Term Follow-Up of Baroreflex Activation Therapy in Resistant Hypertension. <i>Hypertension</i> , 2017, 69, 782-784.	2.7	3
389	Scientific publication activity during COVID-19 shutdown. <i>Clinical Research in Cardiology</i> , 2020, 109, 1443-1445.	3.3	3
390	Inducibility of atrial fibrillation after catheter ablation predicts recurrences of atrial fibrillation: a meta-analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 667-676.	1.2	3
391	Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. <i>Clinical Cardiology</i> , 2021, 44, 665-674.	1.8	3
392	Markers of cholesterol synthesis to cholesterol absorption across the spectrum of non-dialysis CKD: An observational study. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00801.	2.4	3
393	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100818.	1.1	3
394	Experimental Evidence Of The Role Of Renal Sympathetic Denervation For Treating Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2014, 7, 1128.	0.5	3
395	Arterial hypertension - clinical trials update 2022. <i>Hypertension Research</i> , 2022, , .	2.7	3
396	Too much is too much: evidence against dual RAAS inhibition in hypertensives with heart failure symptoms. <i>European Heart Journal</i> , 2015, 36, 899-901.	2.2	2

#	ARTICLE	IF	CITATIONS
397	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1064-1071.	0.9	2
398	Renal denervation in patients with heart failure with preserved ejection fraction: end of the beginning?. <i>European Journal of Heart Failure</i> , 2016, 18, 713-715.	7.1	2
399	High blood pressure in coronary artery disease: when to start treating and what to target?. <i>European Heart Journal</i> , 2018, 39, 3864-3866.	2.2	2
400	Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a Patient With HOCM. <i>JACC: Case Reports</i> , 2020, 2, 384-388.	0.6	2
401	COVID-19 and the heart: insights from the National Societies of Cardiology Journals. <i>European Heart Journal</i> , 2021, 42, 4003-4005.	2.2	2
402	Pharmacotherapy adherence in patients with heart failure: Easier said than done. <i>International Journal of Cardiology</i> , 2021, 332, 135-137.	1.7	2
403	OUP accepted manuscript. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, , .	1.0	2
404	Dear Doctor Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription. <i>Deutsches Ärzteblatt International</i> , 2020, 117, 687-688.	0.9	2
405	Management strategies in heart failure with preserved ejection fraction. <i>Herz</i> , 2022, 47, 332-339.	1.1	2
406	Renal denervation reduces atrial remodeling in hypertensive rats with metabolic syndrome. <i>Basic Research in Cardiology</i> , 2022, 117, .	5.9	2
407	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2682.	2.8	1
408	Drug therapy for the patient with resistant hypertension. <i>Future Cardiology</i> , 2015, 11, 191-202.	1.2	1
409	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. <i>International Journal of Cardiology</i> , 2017, 249, 365.	1.7	1
410	Vena Cava Compression Syndrome in Obesity is Reversed by Bariatric Surgery. <i>American Journal of Medicine</i> , 2018, 131, e291-e292.	1.5	1
411	Physiological monitoring in the complex multimorbid heart failure patient - Conclusions. <i>European Heart Journal Supplements</i> , 2019, 21, M68-M71.	0.1	1
412	Letter on "Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARMACHF randomized controlled trial": reply. <i>European Journal of Heart Failure</i> , 2020, 22, 565-566.	7.1	1
413	Risk prediction with blood pressure during physical activity: A METter of exercise?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 975-977.	1.8	1
414	Atrial fibrillation: selecting patients at risk for cardiovascular events by blood pressure. <i>European Heart Journal</i> , 2020, 41, 4600-4600.	2.2	1

#	ARTICLE	IF	CITATIONS
415	Effects of selective heart rate reduction with ivabradine on LV function and central hemodynamics in patients with chronic coronary syndrome. <i>IJC Heart and Vasculature</i> , 2021, 34, 100757.	1.1	1
416	Differences in management of telemedicine alerts on weekdays and public holidays: Results from the OptiLink heart failure trial. <i>Journal of Telemedicine and Telecare</i> , 2021, , 1357633X2110393.	2.7	1
417	Pathophysiology: The Target for Renal Denervation. , 2015, , 1-7.		1
418	Application in Hypertension of Renal Sympathetic Denervation â€“ A Review. <i>Interventional Cardiology Review</i> , 2013, 8, 124.	1.6	1
419	Treating to protect: current cardiovascular treatment approaches and remaining needs. <i>Medscape Journal of Medicine</i> , 2008, 10 Suppl, S3.	0.6	1
420	Does angiotensin-converting-enzyme inhibitor therapy improve cognitive function in heart failure patients?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 448-449.	3.3	0
421	Response to Letter Regarding Article, â€œRenal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?â€. <i>Circulation Research</i> , 2014, 115, e19-20.	4.5	0
422	The year in Clinical Research in Cardiology: the official Journal of the German Cardiac Society (Deutsche Gesellschaft fÃ¼r Kardiologie â€“ Herz- und Kreislaufforschung). <i>Clinical Research in Cardiology</i> , 2014, 103, 169-171.	3.3	0
423	<i>Primum non nocere</i>: the dangers of deferring heart failure therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 1410-1411.	7.1	0
424	Early reninâ€“angiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes. <i>Evidence-Based Medicine</i> , 2017, 22, 185-186.	0.6	0
425	Overestimation of cardiovascular outcome incidence â€“ Authors' reply. <i>Lancet, The</i> , 2017, 390, 2547.	13.7	0
426	Target blood pressure in high risk cardiovascular patients. <i>Journal of Thoracic Disease</i> , 2017, 9, E877-E878.	1.4	0
427	Arteriovenous Fistula, Blood Pressure, and Shunt Flow: A Thin Line That Separates Beneficial From Detrimental Effects. <i>American Journal of Hypertension</i> , 2019, 32, 935-937.	2.0	0
428	J-curve revisited. <i>European Heart Journal</i> , 2020, 41, 4283-4283.	2.2	0
429	Blood pressure lowering with alcoholâ€“mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E832-E838.	1.7	0
430	Real-world experience with the wearable cardioverter defibrillator: clinical effectiveness and wear-time adherence in patients at high risk for sudden cardiac death. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2021, , 1.	0.8	0
431	Renal Denervation for Chronic Heart Failure. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016, , 281-292.	0.1	0
432	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1068-1075.	0.9	0

#	ARTICLE	IF	CITATIONS
433	Catheter-based renal denervation: treating hypertension or beyond?. Chinese Medical Journal, 2014, 127, 1166-8.	2.3	0
434	Effects of cardiovascular single pill combinations compared with identical multi-pill therapies on healthcare cost and utilization in Germany. Journal of Comparative Effectiveness Research, 2022, 11, 411-422.	1.4	0
435	Ischemic Stroke—A Scientometric Analysis. Frontiers in Neurology, 2022, 13, 893121.	2.4	0
436	MO085: 10-Year Clinical Events Avoided in Diabetic and Chronic Kidney Disease Hypertension Patients Treated With Radiofrequency Renal Denervation: Projections Based on 3-Year Data From the Global Symplicity Registry. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0